surgery versus upfront surgery in resectable disease, as well as a concurrent Cox regression analysis, from the National Cancer Database (NCDB) concluded that PST conferred a significant survival benefit in early stage disease. 21, 22 Given the very low response rates of the regimens used in the studies included in these retrospective analyses, one could potentially conclude that the previously mentioned ability to select patients for surgery based on the biology of their cancer, rather than any notable effect of the PST, was the principal reason for better outcomes to date with this strategy.
More active systemic therapy is needed to prospectively validate this approach and to improve on these results. FOLFIRINOX 8, 15 IV every 28 days) are currently the most active regimens in a metastatic setting, with the former providing a median overall survival of 11.1 months and the latter 8.5 months in recent studies. 23, 24 FOLFIRINOX is now commonly modified with inclusion of pegfilgrastim, and elimination of the 5FU bolus (mFOLFIRINOX), with a resultant reduction in toxicity but not efficacy. 25 Thus, for the purposes of exploring the use of mFOLFIRINOX as PST in resectable pancreatic cancer, we have designed and completed a pilot study with the hypothesis that this regimen will be both feasible and tolerable and will be sufficiently active to provide a platform for future investigation. We chose to complete treatment with a further four cycles of mFOLFIRINOX after surgery, for maximal systemic effect within the bounds of patient tolerance.
| MATERIALS AND METHODS

| Study design and patients
This was a proof-of-concept pilot study conducted at two academic centers in the USA. she was switched to surveillance with follow-up according to standard NCCN guidelines. Patients were to be followed for 5 years after completion of study or until death, whichever occurred first, with visits every 3 months for years 1 and 2 and every 6 months for years 3-5.
Because surgery-related deaths after PST were of concern, there was close monitoring of this adverse event. Specifically, a stopping rule developed by Goldman 27 was used as a guide for early termination due to surgery-related deaths. The stopping rule required that early termination be considered if three deaths occurred in the first fourteen or fewer patients or four deaths in the first thirty-one or fewer patients. Additionally, febrile neutropenia, platelet counts less than 20 × 10 3 /μL, and diarrhea requiring hospitalization were also closely monitored. A stopping rule, based on an acceptable level of 10% and upper limit of 20%, required that early termination be considered if four such adverse events occurred in the first four patients, five such adverse events in the first ten or fewer patients, six such adverse events in the first seventeen or fewer patients, or seven such adverse events in the first twenty-four or fewer patients. The study was monitored by an independent Data and Safety Monitoring Board (DSMB), consisting of two independent medical oncologists, the data manager, the study statistician and a pharmacist, which met monthly to review patient enrollment, serious or unexpected adverse events, those events pertinent to the stopping rules, and any delay in time to surgery or delayed wound healing. Annual non-blinded safety reports, including all serious adverse events, were provided to the IRB.
| Outcomes
The 
| Statistical analysis
This pilot study was conducted using a single-stage design to detect a minimum primary endpoint success rate of 75%, compared with 50% which was considered reasonable in this setting, using a one-sided alpha of 0.15. Twenty-one patients were to be enrolled. If thirteen or fewer patients met the criteria for success, the regimen would not be considered worthy of additional evaluation. This design yields at least 0.85 probability of a positive result if the true success rate is at least 75% and at least 0.90 probability of a negative result if the true success rate is at most 50%. Data were summarized using descriptive statistics.
Point estimates and 95% confidence intervals (CI) were computed for binary endpoints. The Kaplan-Meier method was used to estimate patient's progression free survival (PFS) and overall survival (OS). The log-rank test was used to compare PFS and OS between resection and no resection groups. All analyses were conducted using SAS 9.4 software (SAS Inc., Cary, NC).
| Role of the funding source
As this pilot study was unfunded there were no potential conflicts of interest.
| RESULTS
Twenty-one patients were enrolled between February 4, 2013 and Table 3 summarizes the adverse events. The most common adverse events were diarrhea, anorexia, and fatigue. Grade 4 adverse events were rare, with one event (hypokalemia) preoperatively, and one event (neutropenia) postoperatively. Grade 3 events were more common, but none exceeded 5% of treatment cycles other than diarrhea (6% cycles preoperatively and 7% cycles postoperatively), anorexia and fatigue (9.6% and 5.7% cycles postoperatively, respectively). Dose modifications were required in 30% of patients preoperatively (neuropathy 1; thrombocytopenia 2; neutropenia 3; diarrhea 2) and in 26% of patients postoperatively (neuropathy 3; diarrhea 3; allergic reaction 1) (overlapping toxicities in some patients). 
| DISCUSSION
This study was designed to determine whether PST, using four cycles of mFOLFIRINOX, was both feasible and tolerable in patients with resectable pancreatic cancer and ECOG PS of 0 or 1, and would not compromise an acceptable R0 resection rate. 95% of patients completed all planned PST and were deemed operable, with 81% able to undergo pancreatic resection with an R0 of 94%, thus meeting the primary endpoint of this study. A number of pertinent observations can be made.
First, the modification of FOLFIRINOX used in this study 25 is more tolerable than the original regimen 23 and facilitates completion of therapy with acceptable toxicity. This tolerability means that future studies will likely be able to use up to eight cycles of therapy, or more, as deemed necessary for optimal results. The current SWOG 1505
Intergroup study, which randomizes patients with potentially resectable pancreatic cancer to mFOLFIRINOX versus gemcitabine plus nabpaclitaxel, before and after surgery, uses a total of six cycles preoperatively. A parallel ALLIANCE/Intergroup study A021501, in borderline resectable pancreatic cancer, uses eight cycles of mFOL-FIRINOX versus seven cycles followed by stereotactic radiation. These studies will provide additional toxicity data. We chose to include only those patients with ECOG PS of 0 or 1, as in previous studies exploring a neoadjuvant approach, as these individuals would be expected to be Second, the ability to prform pancreatic resection is not compromised by a primary systemic approach, with resection rates at least as good as those of immediate surgery. The R0 resection rate was excellent (94% of those actually resected, and 76% of patients by intention to treat) and the fact that more than 50% of specimens showed treatment effect with one pathologic CR was encouraging.
The reported margin negative resection rate in patients taken to surgery with or without some form of presurgical therapy is highly variable (17-90%), depending to a large extent on the definitions and methods used. A recent comprehensive review highlights the different methodologies employed, the results, and the controversies surrounding this topic. 28 Thirdly, there was no detectable radiographic or serologic evidence of disease progression while on chemotherapy, within the current limitations of these tests. Third, most eligible patients completed all planned post-surgical mFOLFIRINOX, if the two patients with peri-surgical deaths are censured, with 93% able to do so (66% of all registered patients). We were concerned that this intensive regimen could be a problem following surgery, but toxicity postoperatively was no worse than preoperatively. Dose adjustments were made as needed to account for individual tolerance. It is noteworthy that the completion rate of single agent gemcitabine (the previous standard of care) in all comers in this setting is suboptimal at 62%. 15 Currently the PRODIGE24/AC-CORD24 study is evaluating the use of mFOLFIRINOX versus gemcitabine in the postoperative setting and this will provide more data on the relative tolerability and efficacy of these regimens following surgery. The Alliance/Intergroup A021101 study of perioperative therapy in borderline resectable disease also used four cycles of mFOLFIRINOX in the preoperative setting, but switched to gemcitabine only following surgery; the completion rate of all planned therapy was 41%. 31 The limitations of this study include the necessarily small sample size of a pilot study, inclusion of patients with PS of ECOG 0 or 1 only, the limited number of participating institutions and the fact that more than one pathologist and radiologist reviewed results. In addition, one patient chose to discontinue her participation in the study and was lost to follow up, such that she could not be included in the analysis of PFS and OS. The strengths include the quality control, with each patient reviewed at a multi-disciplinary pancreaticobiliary conference prior to enrollment and at each critical step, the experience of the pancreatic surgeons and medical oncologists, the median duration of follow up of 27.7 months and the close adherence to protocol criteria and guidelines. Radiation Therapy (SBRT) 33 and irreversible electroporation 34 has yet to be determined and will require additional study.
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